Revvity, Inc. announced on May 19, 2025, the launch of its new IDS i20™ analytical random access platform from EUROIMMUN. This instrument enables full automation of chemiluminescence immunoassays (ChLIA).
The IDS i20 platform is a CE marked and FDA listed device, allowing laboratories to consolidate multiple specialty tests on a single instrument. It offers greater reagent capacity and higher test throughput compared to existing offerings.
The versatile instrument can simultaneously run 20 analytes from six diagnostic specialties, including endocrinology, allergy, autoimmune, infectious diseases, Alzheimer’s disease, and therapeutic drug monitoring. It processes up to 140 tests per hour, enhancing efficiency and minimizing hands-on time.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.